Matrix metalloproteinase-9 is elevated in serum of alcohol abusers

European Journal of Clinical Investigation

Volumn 32, Issue 4, 2002, Pages 225-229

  Sillanaukee, P ^a,b   Kalela, A ^a   Seppa K ^a   Hoyhtya M ^c   Nikkari, Seppo T ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Diabor Oy   (Finland)

Author keywords

Alcohol; Atherosclerosis; MMP 9

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DEFICIENT TRANSFERRIN; GAMMA GLUTAMYLTRANSFERASE; GELATINASE B;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ALCOHOL DRINKING; ALCOHOLISM; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TRANSFERRIN;

EID: 0036991979     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00975.x     Document Type: Article

References (26)

1. Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease. A Rev Med 1986;65:242-67.
2. Klatsky AL, Armstrong MA, Friedman GD. Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers. Am J Cardiol 1990;66:1237-42.
3. Keil U, Chambless LE, Doring A, Filipiak B, Stieber J. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology 1997;8:150-6.
4. Gordon T, Doyle JT. Drinking and coronary heart disease: the Albany study. Am Heart J 1985;110:331-4.
5. Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. Epidemiology 1990;1:342-8.
6. Rehm JT, Bondy SJ, Sempos CT, Vuong CV. Alcohol consumption and coronary heart disease morbidity and mortality. Am J Epidemiol 1997;146:495-501.
7. Bengtsson H, Bergqvist D, Ekberg O, Janzon L. A population based screening of abdominal aortic aneurysms (AAA). Eur J Vasc Surg 1991;5:53-7.
8. Partridge CR, Sampson HW, Forough R. Long-term alcohol consumption increases matrix metalloproteinase-2 activity in rat aorta. Life Sci 1999;65:1395-402.
9. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-8.
10. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318-26.
11. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-31.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
13. Nikkari ST, Höyhtyä M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1997;149:1427-33.
14. Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum 1996;39:1747-53.
15. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
16. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991;266:7870-5.
17. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996;78:161-71.
18. Endo K, Maehara Y, Baba H, Yamamoto N, Tomisaki S, Watanabe A et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17:2253-8.
19. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24:1058-62.
20. Kalela A, Pönniö M, Koivu TA, Höyhtyä M, Huhtala H, Sillanaukee P et al. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur J Clin Invest 2000;30:99-104.
21. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998;97:2445-53.
22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
23. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo Aet al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Medical 1993;4:197-250.
24. Vartio T, Baumann M. Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett 1989;255:285-9.
25. Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000;46:183-92.
26. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc Med 1998;3:225-9.